Experts in breast oncology discuss the evolving landscape in early stage and metastatic HER2-positive breast cancer.
HER2+ BC: A Year in Review and Updates from SABCS
Andrew Seidman, MD, provides insight on clinical sequencing for patients with advanced HER2-positive breast cancer.
Hatem Soliman, MD, discusses data presented at the 2020 SABCS for patients with HER2-enriched subtypes that showed benefit from CDK4/6 inhibition.
A discussion on the importance of prognostic tools for early stage breast cancer.
Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.
Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.
EP. 7: Disease-Free Interval and Overall Survival in HER2+ BC
Published: | Updated:
Analysis from the ALTTO (BIG 2-06) trial and the relationship between a short or long disease-free interval and overall survival.
Experts in breast oncology discuss their real-world experience with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer.
Hatem Soliman, MD, reviews statistically significant data from the PERTAIN study, presented at the 2020 San Antonio Breast Cancer Symposium.
EP. 10: Promising Data for Trastuzumab Deruxtecan Combination
Published: | Updated:
Experts in breast oncology discuss the evolving role of trastuzumab deruxtecan for metastatic HER2-positive breast cancer.
Final analysis of data on HER2-positive disease presented at the 2020 San Antonio Breast Cancer Symposium from experts in the field of breast oncology.